Amarin (NASDAQ:AMRN) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Amarin (NASDAQ:AMRN) from a sell rating to a hold rating in a report published on Friday.

Amarin Stock Down 0.8 %

Shares of AMRN opened at $0.53 on Friday. The firm has a market cap of $217.66 million, a PE ratio of -5.89 and a beta of 1.82. The company’s fifty day moving average is $0.56 and its two-hundred day moving average is $0.56. Amarin has a fifty-two week low of $0.43 and a fifty-two week high of $1.11.

Hedge Funds Weigh In On Amarin

Hedge funds have recently made changes to their positions in the stock. Arkfeld Wealth Strategies L.L.C. raised its stake in shares of Amarin by 52.6% in the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 20,000 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Amarin in the 4th quarter valued at $36,000. Generation Capital Management LLC purchased a new position in shares of Amarin in the 4th quarter valued at $50,000. Stonepine Capital Management LLC purchased a new position in shares of Amarin in the 4th quarter valued at $55,000. Finally, Kornitzer Capital Management Inc. KS raised its stake in shares of Amarin by 80.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 42,700 shares during the period. Institutional investors and hedge funds own 22.25% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.